Rigaku Collaborates on X-ray Analysis of Fusuma-e by Maruyama Okyo
Rigaku Corporation, a global solution partner in X-ray analytical devices and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter 'Rigaku') has conducted measurements of fusuma-e in Daijoji, a temple in Mikata-gun, Hyogo Prefecture. Fusuma-e, also called shohekiga, are images drawn on fusuma, traditional sliding partitions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520840612/en/
Measurement using the Thermo Scientific™ Niton™ XL5 Plus, a handheld XRF analyzer
The measurements were conducted as part of a research project to 'restore the original colors of the gold-leaf backing of fusuma-e drawn by Maruyama Okyo (1733–1795), a painter of the mid to late Edo period. The project is being conducted through the collaboration of three researchers: Shinno Yamasoba, assistant chief priest of Daijoji Temple and project leader; Tetsuya Senda, formerly of the National Maritime Research Institute; and Takeshi Tanaka, artist and professor at Tohoku University of Art & Design.
The purpose of the measurements was to investigate scientifically the artistic intention of Maruyama Okyo, the historical context in which he painted, and the impact that restoration would have. The team used the Thermo Scientific™ Niton™ XL5 Plus, a handheld X-ray fluorescence (XRF) analyzer, for its ability to analyze material composition non-destructively. Detailed data were acquired, focusing on the following three areas of interest.
(1) Determining the timing of production of the peacock images
The team measured to determine whether the gold foil used in the two center panels and the two end panels were of the same or different composition. Confirmation that the compositions are different would provide scientific evidence that the fusuma-e were produced at different times.
(2) Use of gold foil to express perspective
Preliminary measurements suggest that gold foil was used on panels with colored drawings of basho (Japanese fiber banana) to produce a bright, reddish tinge, and on panels with ink drawings of peacocks to create a dark, bluish aspect. In this measurement, the compositions of all fusuma were analyzed to examine further whether different color gradations of gold foil were used in two-panel spaces to create perspective (sense of depth). The results are expected to lead to fresh understanding of the expressive techniques of Okyo.
(3) Use of gold foil in the Edo and Meiji eras
The team compared the gold foil Okyo used in the original paintings in the Edo era with the gold foil used in repairs in the early Meiji era (mid-to-late 19th century). This measurement was a precious opportunity to obtain quantitative data on the gold foil used in the Edo era.
These analytical results are expected to be used as a scientific resource to deepen understanding of the painting aches and techniques of Maruyama Okyo.
Rigaku will continue to contribute to the preservation of cultural treasures and transmission of them to future generations through science and technology.
About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations 'To Improve Our World by Powering New Perspectives.'
For details, please visit rigaku-holdings.com/english
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520840612/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Syncell Announces Strategic Co-Marketing Agreement to Advance
LIVERMORE, Calif., & TAIPEI, Taiwan--(BUSINESS WIRE)-- Syncell, Inc., a pioneer in subcellular spatial proteomics, announced a strategic co-marketing agreement with Thermo Fisher Scientific to bring a fully integrated, high-resolution spatial proteomics workflow to the market. The collaboration highlights the power of integrating Syncell's proprietary Microscoop® technology for spatial protein purification with Thermo Fisher's ultra-sensitive Orbitrap™ Astral™ mass spectrometer and newly released Orbitrap™ Astral™ Zoom mass spectrometer. 'The integration of the Syncell Microscoop technology with the Astral Orbitrap mass spectrometer has transformed our capacity to interrogate biology." Share With this collaboration, Thermo Fisher and Syncell will enable researchers to implement unbiased spatial proteomics with high subcellular resolution to investigate the location and organization of proteins across tissues and cells without relying on predefined targets. This marks a major advance from traditional antibody-based spatial methods and introduces new possibilities for comprehensive protein mapping and discovery across biological systems in oncology, neuroscience, drug discovery, immunology, cell biology, and more. 'The integration of the Syncell Microscoop technology with the Astral Orbitrap mass spectrometer has transformed our capacity to interrogate biology,' said Luisa Iruela-Arispe, PhD, chair of the Department of Cell and Developmental Biology at the Northwestern Medicine Feinberg School of Medicine. 'By uniting the nanometer-scale spatial resolution of the Syncell Microscoop technology with the ultra-sensitive detection of the Astral mass spectrometer, we have achieved an analytical capability that pushes the boundaries of cell signaling, revealing spatial and chemical detail that has never before been accessible.' The combined workflow integrates Syncell's Microscoop Mint — a high-precision system that performs real-time, microscopy-guided spatial protein purification — with the Orbitrap Astral mass spectrometer series, delivering unmatched acquisition speed, proteome depth, and spatial resolution. Together, these technologies unlock a hypothesis-free approach to subcellular proteome analysis in fresh and formalin-fixed, paraffin-embedded (FFPE) tissues as well as in cell culture samples. 'This collaboration with Thermo Fisher reinforces our mission to democratize access to high-resolution, unbiased spatial proteomics,' said Jung-Chi Liao, PhD, CEO and founder at Syncell. 'Microscoop's spatial purification technology is an excellent match with Thermo Fisher's Orbitrap Astral mass spectrometer series. By integrating our systems, we are setting a new gold standard for high-resolution proteomic discovery at the cellular and subcellular level.' About Syncell Syncell is a commercial-stage life science company focused on subcellular protein purification and unbiased spatial proteomics analysis. Syncell has commercialized its Microscoop® technology, helping researchers accurately discover new protein components from targeted regions of interest. To date, the company has raised $40 million from investors. To learn more, visit or follow us on Linkedin.
Business Wire
an hour ago
- Business Wire
MediMergent Launches Pilot Program Deploying Virtual Human Advocates to Facilitate Community-Based Clinical Research
ROCKVILLE, Md.--(BUSINESS WIRE)-- MediMergent, LLC, the Real-World Evidence Company, announces the launch of its newest digital platform to enhance patient engagement and education. This AI-driven solution, utilized by pharma, providers, payers, and patients is facilitated by Virtual Human Advocates (VHA) designed to incorporate personalized facial, body, voice, and language preferences of the patient. The platform will be deployed in a pilot program to reduce the workload of study coordinators at community-based research centers. The VHA will assist in screening and recruiting patients and supporting follow-up strategies related to risk assessment, medication adherence, study compliance and retention, safety reporting, emotion detection, and monitoring study activities. The Program, launched in 10 community-based research centers across the US, will leverage point-of-care digital communication tools available in the practice's waiting and examination rooms. By using the 'wait time' in both locations, the VHA will engage the captive audience in conversations related to trials open for recruitment, roles and responsibilities of trial participants, inclusion criteria, and the overall value proposition of participating in a research trial. Sandra Garrett, Ph.D., the CEO of MediMergent states: 'At a time when more research programs are being directed towards community-based medical practices, the number of clinical trial staff has been significantly reduced. Without additional resources, practices are turning away research opportunities. Our VHAs provide intelligent and interactive methods for monitoring and tracking outcomes while communicating and supporting patient compliance and retention. The VHAs fill a critical gap by off-loading select time-consuming activities, thereby freeing up the study personnel to focus on clinical events.' About MediMergent: MediMergent, LLC, a Real-World Evidence Company, supports a suite of AI-driven digital applications for data collection, integration, and analytics deployed in pre- and post-approval research for drugs, biologics, and medical devices. With an emphasis on 'Voice of the Patient' data, including emotion detection, intent, attitudes, behaviors, cognition, and other biomarkers, MediMergent 's technologies can impact patients' Quality of Life, adherence, persistence, stress, anxiety, and other outcome measures. Under an extended public/private partnership with the FDA, MediMergent has commercialized three digital platforms including MediManager ™ for digital management of clinical trials, MediMentor ™ for enhanced patient engagement and education, and MediMetrics ™ a curated data base that integrates multiple sources of Real-World Data and proprietary analytics to generate Real-World Evidence.
Business Wire
a day ago
- Business Wire
Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB's waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt's proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. Share Seek Lab's MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt's components—lysis chemistry, extraction, amplification, and detection—are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications. The Global TB Testing Gap TB kills more than 1.25 million people each year, with nearly one in three cases going undiagnosed. In high-burden, resource-limited settings, centralized molecular tests face major hurdles: Pathogen complexity: MTB's waxy, lipid-rich cell wall has proven intractable to portable lysis methods for decades. Infrastructure dependence: Gold-standard molecular tests require expensive, power-intensive instruments, refrigeration, and highly skilled (or trained) operators. Sample limitations: Sputum collection is challenging for many patients and can deter testing. 'TB diagnostics have long been limited by gaps in both infrastructure and innovation that have often meant severe consequences for patient care and public health,' said Jared Bauer, CEO of Seek Labs. 'Our rapid, point-of-care SeekIt MTB test is designed to enable molecular-level detection in settings where access to equipment and electricity may be limited.' From Sample to Result: A Simplified Workflow At the core of the MTB SeekIt test is a proprietary, single-step chemical lysis buffer, involving a specially-formulated solution that disrupts MTB cells to release their genomic DNA. This breakthrough innovation takes just 15 minutes at room temperature, while competing methods (high-heat incubation or mechanical bead-beating) require longer times plus expensive equipment, specialized technicians, and complex infrastructure. More importantly, the integrated SeekIt test means the lysate itself flows seamlessly into SeekIt's downstream test components: Seek Extraction™ — A proprietary membrane-based binding system, developed and validated by Seek Labs, that rapidly captures MTB DNA without lab instruments. In validation testing, the MTB DNA yield for Seek Extraction was consistently more than 70% when compared to leading spin-column kits. Seek Amplification™ — A proprietary process that exponentially copies DNA at a constant temperature, detecting as few as 10 MTB genomic copies in 30 minutes without thermal cycling (internally validated), the conventional lab-based method. Molecular Lateral Flow Assay (mLFA) — A test strip that delivers clear, visual results in minutes indicating the presence of amplified DNA in a manner that can be optionally paired with the SeekIt mobile app for digital analysis and connectivity. Speed as a Strategy Conventional development of a molecular test for MTB can take a year or more. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. This rapid-deployment approach illustrates how SeekIt can be rapidly developed for numerous high-priority diseases in record time. 'This was more than a fast project; it's proof of our platform's flexibility,' said Kim Wirthlin, Chief Strategy Officer. 'By focusing our innovation on the MTB-specific lysis step for compatibility with our downstream isothermal amplification, we solved one of TB diagnostics' toughest technical challenges and produced a functional investigational prototype in a single quarter.' From Conference to Collaboration Seek Labs will debut the MTB SeekIt prototype at the 2025 Next Generation Dx Conference (August 18–20, 2025, Washington, D.C.), including: Podium Presentation — Enabling Point of Care Diagnostics Track, Tuesday, August 19 at 10:00 AM ET. Scientific Poster — Detailing the proprietary lysis chemistry, rapid development process, and validation data. Seek Labs is actively seeking partners across global health (ministries of health, TB-focused NGOs, and diagnostics distributors in high-burden regions such as sub-Saharan Africa and Southeast Asia) to advance the MTB SeekIt test through clinical validation, regulatory approval, and deployment. 'Innovation means nothing if it doesn't reach people,' said Bauer. 'We want to work with those who share our vision to advance development of accurate, accessible TB testing solutions wherever they're needed most.' About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release contains forward-looking statements, including statements regarding development timelines, clinical validation, regulatory pathways, and potential collaborations. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties—including scientific, regulatory, manufacturing, clinical, and commercial risks—that could cause actual results to differ materially. The MTB SeekIt assay is an investigational device. Limited by Federal law to investigational use.
